Harvard Bioscience, Inc. (HBIO) Earnings History
Annual and quarterly earnings data from 1998 to 2025
Loading earnings history...
HBIO EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
HBIO Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 53.0% | -0.7% | -65.5% |
| 2024 | 58.2% | -6.6% | -13.2% |
| 2023 | 58.9% | 1.7% | -3.0% |
| 2022 | 53.7% | -6.1% | -8.4% |
| 2021 | 56.9% | 1.7% | -0.2% |
Download Data
Export HBIO earnings history in CSV or JSON format
Free sign-in required to download data
Harvard Bioscience, Inc. (HBIO) Earnings Overview
As of May 8, 2026, Harvard Bioscience, Inc. (HBIO) reported trailing twelve-month net income of -$57M, reflecting -357.1% year-over-year growth. The company earned $-1.28 per diluted share over the past four quarters, with a net profit margin of -65.5%.
Looking at the long-term picture, HBIO's historical earnings data spans multiple years. The company achieved its highest annual net income of $19M in fiscal 2010.
Harvard Bioscience, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ITRN ($58M net income, 16.1% margin), BEAT (-$21M net income), MLAB ($4M net income, -0.8% margin), HBIO has room to improve margins relative to the peer group. Compare HBIO vs ITRN →
HBIO Earnings vs Peers
Earnings metrics vs comparable public companies
HBIO Historical Earnings Data (1998–2025)
28 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$57M | -357.1% | $-629,000 | $-1.28 | -65.5% | -0.7% |
| 2024 | -$12M | -263.3% | -$6M | $-0.28 | -13.2% | -6.6% |
| 2023 | -$3M | +64.1% | $2M | $-0.08 | -3.0% | 1.7% |
| 2022 | -$10M | -3204.2% | -$7M | $-0.23 | -8.4% | -6.1% |
| 2021 | $-288,000 | +96.3% | $2M | $-0.01 | -0.2% | 1.7% |
| 2020 | -$8M | -66.6% | $221,000 | $-0.20 | -7.6% | 0.2% |
| 2019 | -$5M | -35.4% | $377,000 | $-0.12 | -4.0% | 0.3% |
| 2018 | -$3M | -300.2% | $984,000 | $-0.10 | -2.9% | 0.8% |
| 2017 | $-865,000 | +79.9% | $-101,000 | $-0.02 | -0.8% | -0.1% |
| 2016 | -$4M | +77.4% | -$3M | $-0.13 | -4.1% | -2.9% |
See HBIO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs HBIO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare HBIO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonHBIO — Frequently Asked Questions
Quick answers to the most common questions about buying HBIO stock.
Is HBIO growing earnings?
HBIO EPS fell to $-1.28, with earnings declining -357.1%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-57M.
What are HBIO's profit margins?
Harvard Bioscience, Inc. net margin is -65.5%, with operating margin at -0.7%. Below-average margins reflect competitive or cost pressures.
How consistent are HBIO's earnings?
HBIO earnings data spans 1998-2025. The declining earnings trend is -357.1% YoY. Historical data enables comparison across business cycles.